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   Insulin glargine, a new long-acting insulin, provides 
constant, peakless insulin release and is designed for once 
daily administration. Satisfaction with treatment (Diabetes 
Treatment Satisfaction Questionnaire (DTSQ) and 
psychological well-being (Well-being Questionnaire 
(W-BQ) were assessed in a multicentre, randomised 
controlled, open clinical trial comparing the effects of 
insulin glargine and NPH human basal insulin, conducted in 
the USA. Analysis of covariance was performed on the 
change from baseline scores, using treatment and pooled 
site as main effects with baseline scores as covariate. 
   The self-completed questionnaires, were administered at 
baseline, and at least once at weeks 8, 20 or 28 to the 474 
participants (235 male and 239 female; mean age 38.6+12.0 
yrs; mean duration of diabetes 17.5+ 10.8 yrs; mean GHb at 
baseline  7.7+1.2 %). Baseline scores of the DTSQ (mean 
28.8+5.5; maximum possible score =36) and of the W-BQ 
(mean 51.6+9.0; maximum possible score = 66) were high 
in this population. While Treatment Satisfaction improved 
in both treatment groups the improvement was more 
pronounced with insulin glargine at all time points and at 
endpoint (last on-treatment assessment). The difference was 
significant at week 20 (change from baseline  +1.66 vs 
+0.76 points; p = 0.0460). Perceived Frequency of 
Hyperglycaemia and Hypoglycaemia were more markedly 
improved in participants treated with insulin glargine. The 
difference was statistically significant for Perceived 
Frequency of Hyperglycaemia at week 8 (p = 0.0162). 
There was also a statistically non-significant trend for better 
outcomes in psychological well-being in  patients treated 
with insulin glargine. Mean W-BQ scores in these patients 
were mostly higher compared with baseline whereas in the 
NPH group they decreased from baseline. Analysis of the 
W-BQ subscales shows that the observed effects on General 
Well-being are mainly attributable to effects on the 
Depression  and  Positive Well-being subscale scores.  
   The psychological outcomes observed in this study 
include small effects on General Well-being which may 
reflect a combination of treatment and study effects. More 
substantial effects were seen on Treatment Satisfaction; 
there was a trend, reaching statistical significance at some 
time points, for improvement with insulin glargine, coupled 
with a decrease in Perceived Frequency of Hyperglycaemia 
and Hypoglycaemia compared with NPH.   
 
 
 
 
